Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL THIRD GENERATION SEQUENCING MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL THIRD GENERATION SEQUENCING MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 EPIDEMIOLOGY BASED MODELLING
2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL THIRD GENERATION SEQUENCING MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 CHALLENGES
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
5.1 PESTEL ANALYSIS
5.2 PORTER’S 5 FORCES MODEL
5.3 STRATEGIC INITIATIVES
6 REGULATORY FRAMEWORK
7 GLOBAL THIRD GENERATION SEQUENCING MARKET, BY PRODUCT
7.1 OVERVIEW
7.2 SEQUENCING INSTRUMENTS
7.2.1 SINGLE-MOLECULE REAL-TIME (SMRT) DEVICES
7.2.1.1. MARKET VLAUE (USD MN)
7.2.1.2. MARKET VOLUME (UNITS)
7.2.1.3. AVERAGE SELLING PRICE (USD)
7.2.2 NANOPORE SEQUENCING DEVICES
7.2.2.1. MARKET VLAUE (USD MN)
7.2.2.2. MARKET VOLUME (UNITS)
7.2.2.3. AVERAGE SELLING PRICE (USD)
7.2.3 OTHERS
7.3 CONSUMABLES
7.3.1 SEQUENCING KIT
7.3.1.1. DNA BASED
7.3.1.1.1. MARKET VLAUE (USD MN)
7.3.1.1.2. MARKET VOLUME (UNITS)
7.3.1.1.3. AVERAGE SELLING PRICE (USD)
7.3.1.2. RNA BASED
7.3.1.2.1. MARKET VLAUE (USD MN)
7.3.1.2.2. MARKET VOLUME (UNITS)
7.3.1.2.3. AVERAGE SELLING PRICE (USD)
7.3.2 LIBRARY PREPARATION KIT
7.3.2.1. MARKET VLAUE (USD MN)
7.3.2.2. MARKET VOLUME (UNITS)
7.3.2.3. AVERAGE SELLING PRICE (USD)
7.3.3 DNA BARCODING KIT
7.3.3.1. BARCODING PRIMER
7.3.3.1.1. MARKET VLAUE (USD MN)
7.3.3.1.2. MARKET VOLUME (UNITS)
7.3.3.1.3. AVERAGE SELLING PRICE (USD)
7.3.3.2. BARCODING ADAPTERS
7.3.3.2.1. MARKET VLAUE (USD MN)
7.3.3.2.2. MARKET VOLUME (UNITS)
7.3.3.2.3. AVERAGE SELLING PRICE (USD)
7.3.3.3. OTHERS
7.3.4 DNA ACCESSORY
7.3.4.1. MIXING PLATES
7.3.4.1.1. MARKET VLAUE (USD MN)
7.3.4.1.2. MARKET VOLUME (UNITS)
7.3.4.1.3. AVERAGE SELLING PRICE (USD)
7.3.4.2. SAMPLE PLATES
7.3.4.2.1. MARKET VLAUE (USD MN)
7.3.4.2.2. MARKET VOLUME (UNITS)
7.3.4.2.3. AVERAGE SELLING PRICE (USD)
7.3.4.3. PIPETTE TIPS
7.3.4.3.1. MARKET VLAUE (USD MN)
7.3.4.3.2. MARKET VOLUME (UNITS)
7.3.4.3.3. AVERAGE SELLING PRICE (USD)
7.3.4.4. TUBE SEPTA
7.3.4.4.1. MARKET VLAUE (USD MN)
7.3.4.4.2. MARKET VOLUME (UNITS)
7.3.4.4.3. AVERAGE SELLING PRICE (USD)
7.3.4.5. OTHERS
7.3.5 BINDING AND CLEANUP KIT
7.3.5.1. INTERNAL CONTROL KITS
7.3.5.1.1. MARKET VLAUE (USD MN)
7.3.5.1.2. MARKET VOLUME (UNITS)
7.3.5.1.3. AVERAGE SELLING PRICE (USD)
7.3.5.2. LOADING CLEAN UP BEAD KIT
7.3.5.2.1. MARKET VLAUE (USD MN)
7.3.5.2.2. MARKET VOLUME (UNITS)
7.3.5.2.3. AVERAGE SELLING PRICE (USD)
7.3.5.3. BINDING BUFFER KIT
7.3.5.3.1. MARKET VLAUE (USD MN)
7.3.5.3.2. MARKET VOLUME (UNITS)
7.3.5.3.3. AVERAGE SELLING PRICE (USD)
7.3.5.4. OTHERS
7.3.6 OTHERS
7.4 SEQUENCING AS SERVICES
7.4.1 MARKET VLAUE (USD MN)
7.4.2 MARKET VOLUME (UNITS)
7.4.3 AVERAGE SELLING PRICE (USD)
7.5 SUPPORTING HARDWARE
7.5.1 MARKET VLAUE (USD MN)
7.5.2 MARKET VOLUME (UNITS)
7.5.3 AVERAGE SELLING PRICE (USD)
8 GLOBAL THIRD GENERATION SEQUENCING MARKET, BY TECHNOLOGY
8.1 OVERVIEW
8.2 SINGLE MOLECULE REAL TIME (SMRT) SEQUENCING (LONG READ)
8.2.1 BY PRODUCT
8.2.1.1. SEQUENCING INSTRUMENTS
8.2.1.2. CONSUMABLES
8.2.1.3. SEQUENCING AS SERVICE
8.2.1.4. SUPPORTIVE HARDWARE
8.2.2 BY USAGE
8.2.2.1. CLINICAL
8.2.2.2. RESEARCH
8.2.3 BY TYPE OF NUCLEOTIDE SEQUENCES
8.2.3.1. RNA
8.2.3.2. DNA
8.3 NANOPORE-BASED SINGLE MOLECULE ANALYSIS TECHNOLOGY (DIRECT LONG READ)
8.3.1 BY PRODUCT
8.3.1.1. SEQUENCING INSTRUMENTS
8.3.1.2. CONSUMABLES
8.3.1.3. SEQUENCING AS SERVICE
8.3.1.4. SUPPORTIVE HARDWARE
8.3.2 BY USAGE
8.3.2.1. CLINICAL
8.3.2.2. RESEARCH
8.3.3 BY TYPE
8.3.3.1. SOLID STATE
8.3.3.2. BIOLOGICAL
8.3.3.3. HYBRID
8.3.4 BY TYPE OF NUCLEOTIDE SEQUENCES
8.3.4.1. RNA
8.3.4.2. DNA
8.4 SINGLE MOLECULE SEQUENCING (SHORT READ)
8.4.1 BY PRODUCT
8.4.1.1. SEQUENCING INSTRUMENTS
8.4.1.2. CONSUMABLES
8.4.1.3. SEQUENCING AS SERVICE
8.4.1.4. SUPPORTIVE HARDWARE
8.4.2 BY USAGE
8.4.2.1. CLINICAL
8.4.2.2. RESEARCH
8.4.3 BY TYPE OF NUCLEOTIDE SEQUENCES
8.4.3.1. RNA
8.4.3.2. DNA
9 GLOBAL THIRD GENERATION SEQUENCING MARKET, BY METHODS
9.1 OVERVIEW
9.2 WHOLE GENOME SEQUENCING
9.3 METAGENOME SEQUENCING
9.4 RNA SEQUENCING
9.5 EPIGENETICS
9.6 TARGETED SEQUENCING
10 GLOBAL THIRD GENERATION SEQUENCING MARKET, BY APPLICATION
10.1 OVERVIEW
10.2 CLINICAL
10.2.1 CLINICAL DIAGNOSTIC
10.2.1.1. RARE DISEASE DIAGNOSIS
10.2.1.2. INFECTIOUS DISEASE DIAGNOSIS
10.2.1.3. CANCER DIAGNOSIS
10.2.1.4. OTHERS
10.2.2 FORENSIC
10.2.3 RETYPEIVE HEALTH
10.2.4 PRENATAL TESTING
10.2.5 OTHERS
10.3 RESEARCH
10.3.1 EPIGENETICS
10.3.1.1. HUMAN AND EUKARYOTE EPIGENETICS
10.3.1.2. MICROBIAL EPIGENETICS
10.3.2 DRUG DISCOVERY
10.3.2.1. ONCLOLOGY
10.3.2.2. RARE DISEASES
10.3.2.3. GENETIC DISORDERS
10.3.2.4. OTHERS
10.3.3 METAGENOMICS
10.3.4 OTHERS
11 GLOBAL THIRD GENERATION SEQUENCING MARKET, BY WORK FLOW
11.1 OVERVIEW
11.2 LIBRARY PREPARATION
11.3 SEQUENCING
11.4 DATA ANALYSIS
11.5 OTHERS
12 GLOBAL THIRD GENERATION SEQUENCING MARKET, BY TYPE OF NUCLEOTIDE SEQUENCES
12.1 OVERVIEW
12.2 DNA
12.3 RNA
13 GLOBAL THIRD GENERATION SEQUENCING MARKET, BY END USER
13.1 OVERVIEW
13.2 HOSPITALS
13.3 ACADEMIC & RESEARCH INSTITUTES
13.4 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIESS
13.5 CLINICAL AND DIAGNOSTIC LABORATORIES
13.6 OTHERS
14 U.S. DENTAL DEVICES AND CONSUMABLES MARKET, BY DISTRIBUTION CHANNEL
14.1 OVERVIEW
14.2 DIRECT TENDERS
14.3 RETAIL SALES
14.4 OTHERS
15 GLOBAL THIRD GENERATION SEQUENCING MARKET, BY REGION
15.1 GLOBAL THIRD GENERATION SEQUENCING MARKET (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
15.2 NORTH AMERICA
15.2.1 U.S.
15.2.1.1. U.S THIRD GENERATION SEQUENCING MARKET, BY PRODUCT
15.2.1.2. U.S THIRD GENERATION SEQUENCING MARKET, BY TECHNOLOGY
15.2.1.3. U.S THIRD GENERATION SEQUENCING MARKET, BY METHODS
15.2.1.4. U.S THIRD GENERATION SEQUENCING MARKET, BY WORKFLOW
15.2.1.5. U.S THIRD GENERATION SEQUENCING MARKET, BY TYPE OF NUCLEOTIDE SEQUENCED
15.2.1.6. U.S THIRD GENERATION SEQUENCING MARKET, BY APPLICATIONS
15.2.1.7. U.S THIRD GENERATION SEQUENCING MARKET, BY END USER
15.2.1.8. U.S THIRD GENERATION SEQUENCING MARKET, BY DISTRIBUTION CHANNELS
15.2.2 CANADA
15.2.3 MEXICO
15.3 EUROPE
15.3.1 GERMANY
15.3.2 FRANCE
15.3.3 U.K.
15.3.4 FINLAND
15.3.5 DENMARK
15.3.6 NORWAY
15.3.7 POLAND
15.3.8 ITALY
15.3.9 SPAIN
15.3.10 RUSSIA
15.3.11 TURKEY
15.3.12 BELGIUM
15.3.13 NETHERLANDS
15.3.14 SWITZERLAND
15.3.15 SWEDEN
15.3.16 REST OF EUROPE
15.4 ASIA-PACIFIC
15.4.1 JAPAN
15.4.2 CHINA
15.4.3 SOUTH KOREA
15.4.4 INDIA
15.4.5 SINGAPORE
15.4.6 THAILAND
15.4.7 INDONESIA
15.4.8 MALAYSIA
15.4.9 PHILIPPINES
15.4.10 AUSTRALIA
15.4.11 NEW ZEALAND
15.4.12 VIETNAM
15.4.13 TAIWAN
15.4.14 REST OF ASIA-PACIFIC
15.4.15
15.5 SOUTH AMERICA
15.5.1 BRZIL
15.5.2 ARGENTINA
15.5.3 REST OF SOUTH AMERICA
15.6 MIDDLE EAST AND AFRICA
15.6.1 SOUTH AFRICA
15.6.2 SAUDI ARABIA
15.6.3 UAE
15.6.4 EGYPT
15.6.5 KUWAIT
15.6.6 OMAN
15.6.7 ISRAEL
15.6.8 BAHRAIN
15.6.9 REST OF MIDDLE EAST AND AFRICA
15.6.10 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
16 GLOBAL THIRD GENERATION SEQUENCING MARKET, SWOT AND DBMR ANALYSIS
17 GLOBAL THIRD GENERATION SEQUENCING MARKET, COMPANY LANDSCAPE
17.1 COMPANY SHARE ANALYSIS: GLOBAL
17.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
17.3 COMPANY SHARE ANALYSIS: EUROPE
17.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
17.5 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA
17.6 COMPANY SHARE ANALYSIS: SOUTH AMERICA
17.7 MERGERS & ACQUISITIONS
17.8 NEW PRODUCT DEVELOPMENT & APPROVALS
17.9 EXPANSIONS
17.1 REGULATORY CHANGES
17.11 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
18 GLOBAL THIRD GENERATION SEQUENCING MARKET, COMPANY PROFILE
18.1 PACIFIC BIOSCIENCES OF CALIFOENICA INC
18.1.1 COMPANY OVERVIEW
18.1.2 REVENUE ANALYSIS
18.1.3 GEOGRAPHIC PRESENCE
18.1.4 PRODUCT PORTFOLIO
18.1.5 RECENT DEVELOPMENTS
18.2 ILLUMINA
18.2.1 COMPANY OVERVIEW
18.2.2 REVENUE ANALYSIS
18.2.3 GEOGRAPHIC PRESENCE
18.2.4 PRODUCT PORTFOLIO
18.2.5 RECENT DEVELOPMENTS
18.3 OXFORD NANAOPORE TECHNOLOGIES
18.3.1 COMPANY OVERVIEW
18.3.2 REVENUE ANALYSIS
18.3.3 GEOGRAPHIC PRESENCE
18.3.4 PRODUCT PORTFOLIO
18.3.5 RECENT DEVELOPMENTS
18.4 GENXONE S.A
18.4.1 COMPANY OVERVIEW
18.4.2 REVENUE ANALYSIS
18.4.3 GEOGRAPHIC PRESENCE
18.4.4 PRODUCT PORTFOLIO
18.4.5 RECENT DEVELOPMENTS
18.5 F- HOFFMANN LA ROCHE
18.5.1 COMPANY OVERVIEW
18.5.2 REVENUE ANALYSIS
18.5.3 GEOGRAPHIC PRESENCE
18.5.4 PRODUCT PORTFOLIO
18.5.5 RECENT DEVELOPMENTS
18.6 QUANTAPORE
18.6.1 COMPANY OVERVIEW
18.6.2 REVENUE ANALYSIS
18.6.3 GEOGRAPHIC PRESENCE
18.6.4 PRODUCT PORTFOLIO
18.6.5 RECENT DEVELOPMENTS
18.7 FG TECHNOLOGIES
18.7.1 COMPANY OVERVIEW
18.7.2 REVENUE ANALYSIS
18.7.3 GEOGRAPHIC PRESENCE
18.7.4 PRODUCT PORTFOLIO
18.7.5 RECENT DEVELOPMENTS
18.8 BASECLEAR B.V
18.8.1 COMPANY OVERVIEW
18.8.2 REVENUE ANALYSIS
18.8.3 GEOGRAPHIC PRESENCE
18.8.4 PRODUCT PORTFOLIO
18.8.5 RECENT DEVELOPMENTS
18.9 GARVAN INSTITUTE
18.9.1 COMPANY OVERVIEW
18.9.2 REVENUE ANALYSIS
18.9.3 GEOGRAPHIC PRESENCE
18.9.4 PRODUCT PORTFOLIO
18.9.5 RECENT DEVELOPMENTS
18.1 THERMOFISHER SCIENTIFIC INC
18.10.1 COMPANY OVERVIEW
18.10.2 REVENUE ANALYSIS
18.10.3 GEOGRAPHIC PRESENCE
18.10.4 PRODUCT PORTFOLIO
18.10.5 RECENT DEVELOPMENTS
18.11 PERKIN ELMER INC
18.11.1 COMPANY OVERVIEW
18.11.2 REVENUE ANALYSIS
18.11.3 GEOGRAPHIC PRESENCE
18.11.4 PRODUCT PORTFOLIO
18.11.5 RECENT DEVELOPMENTS
18.12 NOVOGENE CORPORATION
18.12.1 COMPANY OVERVIEW
18.12.2 REVENUE ANALYSIS
18.12.3 GEOGRAPHIC PRESENCE
18.12.4 PRODUCT PORTFOLIO
18.12.5 RECENT DEVELOPMENTS
18.13 GENEWIZ INC
18.13.1 COMPANY OVERVIEW
18.13.2 REVENUE ANALYSIS
18.13.3 GEOGRAPHIC PRESENCE
18.13.4 PRODUCT PORTFOLIO
18.13.5 RECENT DEVELOPMENTS
18.14 LEXOGEN GMBH
18.14.1 COMPANY OVERVIEW
18.14.2 REVENUE ANALYSIS
18.14.3 GEOGRAPHIC PRESENCE
18.14.4 PRODUCT PORTFOLIO
18.14.5 RECENT DEVELOPMENTS
18.15 MACROGEN INC
18.15.1 COMPANY OVERVIEW
18.15.2 REVENUE ANALYSIS
18.15.3 GEOGRAPHIC PRESENCE
18.15.4 PRODUCT PORTFOLIO
18.15.5 RECENT DEVELOPMENTS
18.16 PROMEGA CORPORATION
18.16.1 COMPANY OVERVIEW
18.16.2 REVENUE ANALYSIS
18.16.3 GEOGRAPHIC PRESENCE
18.16.4 PRODUCT PORTFOLIO
18.16.5 RECENT DEVELOPMENTS
18.17 DNA TECHNOLOGIES CORE
18.17.1 COMPANY OVERVIEW
18.17.2 REVENUE ANALYSIS
18.17.3 GEOGRAPHIC PRESENCE
18.17.4 PRODUCT PORTFOLIO
18.17.5 RECENT DEVELOPMENTS
18.18 TATAA BIOCENTER
18.18.1 COMPANY OVERVIEW
18.18.2 REVENUE ANALYSIS
18.18.3 GEOGRAPHIC PRESENCE
18.18.4 PRODUCT PORTFOLIO
18.18.5 RECENT DEVELOPMENTS
18.19 UNIVERSAL SEQUENCING TECHNOLOGY
18.19.1 COMPANY OVERVIEW
18.19.2 REVENUE ANALYSIS
18.19.3 GEOGRAPHIC PRESENCE
18.19.4 PRODUCT PORTFOLIO
18.19.5 RECENT DEVELOPMENTS
*NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST
19 RELATED REPORTS
20 CONCLUSION
21 QUESTIONNAIRE
22 ABOUT DATA BRIDGE MARKET RESEARCH
